NFKB1 and neoplasm: Paclitaxel, a known TLR-4 ligand, enhances NF-κB activity and up-regulates expression of X-linked inhibitor of apoptosis (XIAP) and pro-inflammatory cytokines known to promote tumor survival and progression in EOC.